Company profile
Tengion, Inc.
OTC: TNGNQ · Healthcare · Biotechnology
PublicHQ Winston-Salem, Reports USD
#1164 of 1,420 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 18
v0.1 · 5/100 weight · pillars only
↑ disclosure history, workforce scale · ↓ market scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.5M
Employees
25
as of 2026-08-30
Market cap
$402
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02013
Net income-$26.5M-$26.5M2013
Operating income-$16.6M-$16.6M2013
Total assets$25.7M$25.7M2013
Liabilities$42.6M$42.6M2013
Equity-$16.9M-$16.9M2013
Revenue trend
FY2007 – FY2013 · USD
FY07
FY08
FY09
FY10
FY11
FY12
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tengion, Inc.’s revenue?
Tengion, Inc. booked $0 in FY2013 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Life Stem Genetics Inc.——Innovation1 Biotech Inc.——Xeno Transplants Corporation——Claritas Pharmaceuticals, Inc.——Sienna Biopharmaceuticals, Inc.——eFFECTOR Therapeutics, Inc.——Key facts
CEODavid I. Scheer
SectorHealthcare
IndustryBiotechnology
HeadquartersWinston-Salem, null
ExchangeOTC: TNGNQ
Employees25
IPO date2022-11-23
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.